Tag Archives: Nimbus Therapeutics

The Book of Nimbus
April 27, 2023

By Jeb Keiper, CEO of Nimbus Therapeutics, as part of the From The Trenches feature of LifeSciVC Forward Nimbus Therapeutics began 14 years ago.  The premise at the time was that putting computational chemistry in the primary position for new

Leave a comment

Takeda Acquires Nimbus’ Tyk2 Autoimmune Program
December 13, 2022

Today we’re thrilled to announce the acquisition of Nimbus’ allosteric Tyk2 autoimmune program by Takeda for up to $6 billion in an upfront and future milestones. As a potential best-in-class asset in the significant new therapeutic category of selective Tyk2

Leave a comment

Talent In The Biotech Gig Economy
January 31, 2017

This blog was written by Jeb Keiper, CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC. Walking the streets of Union Square in mid-January torrential rain, we had the good fortune of sharing the


Nimbus Delivers Its Apollo Mission: A $1.2B Gilead Partnership
April 4, 2016

Today Gilead announced the acquisition of Nimbus’ lead program targeting NASH and related metabolic disorders for $400M upfront and up to another $800M in development and regulatory milestones (here). This transformative deal is the culmination of over five years of work on

Leave a comment